Cargando…

Drug affinity-responsive target stability unveils filamins as biological targets for artemetin, an anti-cancer flavonoid

Artemetin is a valuable 5-hydroxy-3,6,7,3′,4′-pentamethoxyflavone present in many different medicinal plants with very good oral bioavailability and drug-likeness values, owing to numerous bioactivities, such as anti-inflammatory and anti-cancer ones. Here, a multi-disciplinary plan has been settled...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferraro, Giusy, Belvedere, Raffaella, Petrella, Antonello, Tosco, Alessandra, Stork, Björn, Salamone, Stefano, Minassi, Alberto, Pollastro, Federica, Morretta, Elva, Monti, Maria Chiara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452882/
https://www.ncbi.nlm.nih.gov/pubmed/36090055
http://dx.doi.org/10.3389/fmolb.2022.964295
_version_ 1784785014994501632
author Ferraro, Giusy
Belvedere, Raffaella
Petrella, Antonello
Tosco, Alessandra
Stork, Björn
Salamone, Stefano
Minassi, Alberto
Pollastro, Federica
Morretta, Elva
Monti, Maria Chiara
author_facet Ferraro, Giusy
Belvedere, Raffaella
Petrella, Antonello
Tosco, Alessandra
Stork, Björn
Salamone, Stefano
Minassi, Alberto
Pollastro, Federica
Morretta, Elva
Monti, Maria Chiara
author_sort Ferraro, Giusy
collection PubMed
description Artemetin is a valuable 5-hydroxy-3,6,7,3′,4′-pentamethoxyflavone present in many different medicinal plants with very good oral bioavailability and drug-likeness values, owing to numerous bioactivities, such as anti-inflammatory and anti-cancer ones. Here, a multi-disciplinary plan has been settled and applied for identifying the artemetin target(s) to inspect its mechanism of action, based on drug affinity-responsive target stability and targeted limited proteolysis. Both approaches point to the disclosure of filamins A and B as direct artemetin targets in HeLa cell lysates, also giving detailed insights into the ligand/protein-binding sites. Interestingly, also 8-prenyl-artemetin, which is an artemetin more permeable semisynthetic analog, directly interacts with filamins A and B. Both compounds alter filamin conformation in living HeLa cells with an effect on cytoskeleton disassembly and on the disorganization of the F-actin filaments. Both the natural compound and its derivative are able to block cell migration, expectantly acting on tumor metastasis occurrence and development.
format Online
Article
Text
id pubmed-9452882
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94528822022-09-09 Drug affinity-responsive target stability unveils filamins as biological targets for artemetin, an anti-cancer flavonoid Ferraro, Giusy Belvedere, Raffaella Petrella, Antonello Tosco, Alessandra Stork, Björn Salamone, Stefano Minassi, Alberto Pollastro, Federica Morretta, Elva Monti, Maria Chiara Front Mol Biosci Molecular Biosciences Artemetin is a valuable 5-hydroxy-3,6,7,3′,4′-pentamethoxyflavone present in many different medicinal plants with very good oral bioavailability and drug-likeness values, owing to numerous bioactivities, such as anti-inflammatory and anti-cancer ones. Here, a multi-disciplinary plan has been settled and applied for identifying the artemetin target(s) to inspect its mechanism of action, based on drug affinity-responsive target stability and targeted limited proteolysis. Both approaches point to the disclosure of filamins A and B as direct artemetin targets in HeLa cell lysates, also giving detailed insights into the ligand/protein-binding sites. Interestingly, also 8-prenyl-artemetin, which is an artemetin more permeable semisynthetic analog, directly interacts with filamins A and B. Both compounds alter filamin conformation in living HeLa cells with an effect on cytoskeleton disassembly and on the disorganization of the F-actin filaments. Both the natural compound and its derivative are able to block cell migration, expectantly acting on tumor metastasis occurrence and development. Frontiers Media S.A. 2022-08-25 /pmc/articles/PMC9452882/ /pubmed/36090055 http://dx.doi.org/10.3389/fmolb.2022.964295 Text en Copyright © 2022 Ferraro, Belvedere, Petrella, Tosco, Stork, Salamone, Minassi, Pollastro, Morretta and Monti. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Molecular Biosciences
Ferraro, Giusy
Belvedere, Raffaella
Petrella, Antonello
Tosco, Alessandra
Stork, Björn
Salamone, Stefano
Minassi, Alberto
Pollastro, Federica
Morretta, Elva
Monti, Maria Chiara
Drug affinity-responsive target stability unveils filamins as biological targets for artemetin, an anti-cancer flavonoid
title Drug affinity-responsive target stability unveils filamins as biological targets for artemetin, an anti-cancer flavonoid
title_full Drug affinity-responsive target stability unveils filamins as biological targets for artemetin, an anti-cancer flavonoid
title_fullStr Drug affinity-responsive target stability unveils filamins as biological targets for artemetin, an anti-cancer flavonoid
title_full_unstemmed Drug affinity-responsive target stability unveils filamins as biological targets for artemetin, an anti-cancer flavonoid
title_short Drug affinity-responsive target stability unveils filamins as biological targets for artemetin, an anti-cancer flavonoid
title_sort drug affinity-responsive target stability unveils filamins as biological targets for artemetin, an anti-cancer flavonoid
topic Molecular Biosciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452882/
https://www.ncbi.nlm.nih.gov/pubmed/36090055
http://dx.doi.org/10.3389/fmolb.2022.964295
work_keys_str_mv AT ferrarogiusy drugaffinityresponsivetargetstabilityunveilsfilaminsasbiologicaltargetsforartemetinananticancerflavonoid
AT belvedereraffaella drugaffinityresponsivetargetstabilityunveilsfilaminsasbiologicaltargetsforartemetinananticancerflavonoid
AT petrellaantonello drugaffinityresponsivetargetstabilityunveilsfilaminsasbiologicaltargetsforartemetinananticancerflavonoid
AT toscoalessandra drugaffinityresponsivetargetstabilityunveilsfilaminsasbiologicaltargetsforartemetinananticancerflavonoid
AT storkbjorn drugaffinityresponsivetargetstabilityunveilsfilaminsasbiologicaltargetsforartemetinananticancerflavonoid
AT salamonestefano drugaffinityresponsivetargetstabilityunveilsfilaminsasbiologicaltargetsforartemetinananticancerflavonoid
AT minassialberto drugaffinityresponsivetargetstabilityunveilsfilaminsasbiologicaltargetsforartemetinananticancerflavonoid
AT pollastrofederica drugaffinityresponsivetargetstabilityunveilsfilaminsasbiologicaltargetsforartemetinananticancerflavonoid
AT morrettaelva drugaffinityresponsivetargetstabilityunveilsfilaminsasbiologicaltargetsforartemetinananticancerflavonoid
AT montimariachiara drugaffinityresponsivetargetstabilityunveilsfilaminsasbiologicaltargetsforartemetinananticancerflavonoid